| Revenue growth | 23.6% YoY in FY26; 32.8% YoY in Q4 FY26. |
|---|---|
| Margins | Resilient; EBITDA margins held in 19%-20% band for 4 years. |
| Demand visibility | Strong; 100%+ net revenue retention and broadening customer base. |
| Management confidence | High; entering FY27 with confidence and strong pipeline. |
Growth
FY26 revenue up 23.6% in INR; Q4 revenue up 32.8% YoY to INR 10,034M. $1M+ clients grew 29% to 53.
Outlook
Entering FY27 with momentum; focus on GenAI-native workflows and integrating recent BioPharm acquisition. Final dividend of ₹2.25 proposed.
Risks
Higher non-cash charges impacting reported profits; potential macro-driven cycle-time compression in pharma spend.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹605.45
- Market cap
- ₹14,586 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.4×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr